Sandu Pharmaceuticals Limited

BSE:524703 Stock Report

Market Cap: ₹544.8m

Sandu Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Sandu Pharmaceuticals has been growing earnings at an average annual rate of 15%, while the Personal Products industry saw earnings growing at 10.6% annually. Revenues have been growing at an average rate of 6.5% per year. Sandu Pharmaceuticals's return on equity is 3.6%, and it has net margins of 2.2%.

Key information

15.0%

Earnings growth rate

8.0%

EPS growth rate

Personal Products Industry Growth7.9%
Revenue growth rate6.5%
Return on equity3.6%
Net Margin2.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sandu Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524703 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24678151770
30 Jun 2466715990
31 Mar 24673151780
31 Dec 23669111660
30 Sep 23666141690
30 Jun 23665121690
31 Mar 23653151700
31 Dec 22615151480
30 Sep 22636151430
30 Jun 22647161430
31 Mar 22655161390
31 Dec 21682171230
30 Sep 21648151320
30 Jun 2164415870
31 Mar 21588111180
31 Dec 2055771330
30 Sep 2053161180
30 Jun 2047741170
31 Mar 2048471170
31 Dec 1949471280
30 Sep 1950461190
30 Jun 195077630
31 Mar 1949471250
31 Dec 185119950
30 Sep 18503141010
30 Jun 1853314630
31 Mar 184916960
31 Dec 17521-3730
30 Sep 17468-4720
30 Jun 17415-2730
31 Mar 17428-4750
31 Dec 164495670
30 Sep 164436640
30 Jun 164265460
31 Mar 164115600
31 Dec 1541131330
30 Sep 1540731310
30 Jun 1540041390
31 Mar 153944560
31 Dec 1438161090
30 Sep 1437151080
30 Jun 143675340
31 Mar 1435951060
31 Dec 1338161250

Quality Earnings: 524703 has high quality earnings.

Growing Profit Margin: 524703's current net profit margins (2.2%) are higher than last year (2.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524703's earnings have grown by 15% per year over the past 5 years.

Accelerating Growth: 524703's earnings growth over the past year (3.3%) is below its 5-year average (15% per year).

Earnings vs Industry: 524703 earnings growth over the past year (3.3%) did not outperform the Personal Products industry 24.4%.

Return on Equity

High ROE: 524703's Return on Equity (3.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 03:43
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sandu Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution